International Phase I/II Expansion Trial of the MEK Inhibitor Selumetinib in Combination With Dexamethasone for the Treatment of Relapsed/Refractory RAS-pathway Mutated Paediatric and Adult Acute Lymphoblastic Leukaemia
Phase of Trial: Phase I/II
Latest Information Update: 20 Dec 2019
Price : $35 *
At a glance
- Drugs Dexamethasone (Primary) ; Selumetinib (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms SeluDex
- 20 Nov 2019 Planned End Date changed from 17 Mar 2021 to 17 Dec 2020.
- 20 Nov 2019 Planned primary completion date changed from 17 Mar 2021 to 17 Jun 2020.
- 10 Oct 2018 New source identified and integrated. [ClinicalTrials.gov: US National Institutes of Health].